06/10/2025 10:00
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approv...

Rio becomes the global capital of fact-checking - AFP steps up

From June 25 to 27, AFP will play an active role at Global Fact 12, the world’s largest summit dedicated to fact-checking, taking place this year in Rio de Janeiro and organized by the International Fact-Checking Network (IFCN).

From June 25 to 27, AFP will play an active role at Global Fact 12, the world’s largest summit dedicated to fact-checking, taking place this year in Rio de Janeiro and organized by the International Fact-Checking Network (IFCN).
06/26/2025 07:02
KAYTUS Enhances KSManage for Intelligent Management of Liquid-Cooled AI Data Centers

KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has announced the release of the enhanced KSManage V2.3, its advanced device management platform for AI data centers. The latest version introduces expanded monitoring and control capabilities tailored for GB200 and B200 systems, including integrated liquid cooling detection features. Leveraging intelligent automation, KSManage V2.3 enables AI data centers to operate with greater precision, efficiency, and sustainability,...

06/10/2025 10:30
Horizon3.ai Raises $100M to Cement Leadership in Autonomous Security

Horizon3.ai, the company behind the NodeZero® Autonomous Security Platform, today announced a $100 million Series D funding round led by NEA, with participation from SignalFire, Craft Ventures and 9Yards Capital. As part of the investment, Lila Tretikov, Partner and Head of AI Strategy at NEA and former Deputy CTO of Microsoft, will join the Horizon3.ai Board of Directors. “Over the past four years, we’ve proven that using AI to hack companies isn’t science fiction—it’s real, and it’s deliver...

07/01/2025 11:34
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further improvement in CFTR pr...

06/10/2025 10:59
Fedrigoni and Palantir Partner to Accelerate Operational Transformation with AI

Palantir Technologies Inc. (NASDAQ: PLTR) today announced a multi-year partnership with Fedrigoni, a global reference manufacturer of specialty papers for packaging and other creative applications, self-adhesive labels, graphic supports for visual communication, and RFID. This strategic alliance aims to accelerate Fedrigoni's digital transformation by leveraging advanced AI capabilities and Palantir's innovative solutions. Initially focused on stock optimization and demand forecasting, the part...

Subscribe to